[{"address1": "116 Huntington Avenue", "address2": "Suite 703", "city": "Boston", "state": "MA", "zip": "02116", "country": "United States", "phone": "617 468 4219", "website": "https://www.bicara.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.", "companyOfficers": [{"maxAge": 1, "name": "Ms. Claire  Mazumdar Clemon M.B.A., Ph.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 650000, "exercisedValue": 0, "unexercisedValue": 578357}, {"maxAge": 1, "name": "Mr. Ryan  Cohlhepp Pharm.D.", "age": 47, "title": "President, COO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 660000, "exercisedValue": 0, "unexercisedValue": 103783}, {"maxAge": 1, "name": "Mr. Ivan  Hyep M.B.A.", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 597500, "exercisedValue": 0, "unexercisedValue": 77109}, {"maxAge": 1, "name": "Ms. Lara S. Meisner J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel  Salazar", "title": "SVP of R&D Strategy and Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sathish  Hasige Ph.D.", "title": "Senior VP and Head of Technical Operations & Supply Chain", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Raben M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Angela  Windt", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeltje  Schulten M.B.A., M.D.", "title": "Senior Vice President of Clinical & Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean-Paul  Rodrique", "title": "Senior VP & Global Head of Quality Assurance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 18.045, "open": 17.88, "dayLow": 17.301, "dayHigh": 19.005, "regularMarketPreviousClose": 18.045, "regularMarketOpen": 17.88, "regularMarketDayLow": 17.301, "regularMarketDayHigh": 19.005, "forwardPE": -11.877854, "volume": 310248, "regularMarketVolume": 310248, "averageVolume": 355168, "averageVolume10days": 331390, "averageDailyVolume10Day": 331390, "bid": 13.4, "ask": 18.27, "bidSize": 200, "askSize": 100, "marketCap": 952273024, "fiftyTwoWeekLow": 17.301, "fiftyTwoWeekHigh": 28.09, "fiftyDayAverage": 21.2938, "twoHundredDayAverage": 22.18677, "currency": "USD", "enterpriseValue": 431856896, "floatShares": 31521176, "sharesOutstanding": 54415600, "sharesShort": 2347100, "sharesShortPriorMonth": 1690473, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0431, "heldPercentInsiders": 0.06262, "heldPercentInstitutions": 0.67003995, "shortRatio": 7.26, "impliedSharesOutstanding": 54415600, "bookValue": 9.365, "priceToBook": 1.86866, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -59478000, "trailingEps": -1.09, "forwardEps": -1.61, "enterpriseToEbitda": -6.224, "52WeekChange": -0.2524562, "SandP52WeekChange": 0.2764505, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BCAX", "underlyingSymbol": "BCAX", "shortName": "Bicara Therapeutics Inc.", "longName": "Bicara Therapeutics Inc.", "firstTradeDateEpochUtc": 1726234200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "89c17e6e-41f3-3d01-85f9-cd0e48aa9b6d", "messageBoardId": "finmb_674698236", "gmtOffSetMilliseconds": -18000000, "currentPrice": 17.5, "targetHighPrice": 47.0, "targetLowPrice": 36.0, "targetMeanPrice": 40.5475, "targetMedianPrice": 39.595, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 520758016, "totalCashPerShare": 9.571, "ebitda": -69384000, "totalDebt": 445000, "quickRatio": 35.961, "currentRatio": 36.014, "debtToEquity": 0.087, "operatingCashflow": -52755000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]